{
    "clinical_study": {
        "@rank": "117836", 
        "arm_group": [
            {
                "arm_group_label": "AC-170 0.24%", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "AC-170 0%", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety of AC-170 0.24% used twice daily in\n      Healthy Adult Subjects and in Pediatric subjects with a history or family history of atopic\n      disease (including allergic conjunctivitis)."
        }, 
        "brief_title": "A Multi-Center Study Evaluating the Safety of AC-170 0.24%", 
        "condition": "Atopc Disease (Including Allergic Conjunctivitis)", 
        "condition_browse": {
            "mesh_term": [
                "Conjunctivitis", 
                "Conjunctivitis, Allergic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  at least 2 years of age\n\n          -  be able to self-administer eye drops or have a parent/legal guardian available for\n             this purpose\n\n          -  if less than 18 years old have a history or family history of atopic disease\n             (including allergic conjunctivitis)\n\n          -  have ocular health within normal limits\n\n        Exclusion Criteria:\n\n          -  known contraindications or sensitivities to the study medication or its components\n\n          -  any ocular condition that, in the opinion of the investigator, could affect the\n             subjects safety trial parameters\n\n          -  use of disallowed medication during the period indicated prior to the enrollment or\n             during the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": {
            "#text": "501", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 29, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02132169", 
            "org_study_id": "14-100-0006"
        }, 
        "intervention": [
            {
                "arm_group_label": "AC-170 0.24%", 
                "intervention_name": "Drug: AC-170 0.24%", 
                "intervention_type": "Drug", 
                "other_name": "1 drop in each eye 2 times daily for up to 6 weeks"
            }, 
            {
                "arm_group_label": "AC-170 0%", 
                "intervention_name": "AC-170 0%", 
                "intervention_type": "Drug", 
                "other_name": "1 drop in each eye 2 times daily for up to 6 weeks"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 5, 2014", 
        "location": {
            "contact": {
                "last_name": "Allie Griffin", 
                "phone": "978-685-8900"
            }, 
            "facility": {
                "address": {
                    "city": "Andover", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "01810"
                }, 
                "name": "Andover Eye Associates"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 0.24% Ophthalmic Solution Used Twice Daily in Healthy Adult Subjects and in Pediatric Subjects With a History or Family History of Atopic Disease (Including Allergic Conjunctivitis)", 
        "overall_contact": {
            "email": "tcavanagh@aciexrx.com", 
            "last_name": "Tom Cavanagh", 
            "phone": "917-969-9339"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Tolerability of AC 170 0.024% compared to its vehicle will  be measured at Visit 1-3. Subjects will assess their comfort based on an approved scale.", 
            "measure": "Tolerability of AC 170 0.24% compared to its vehicle", 
            "safety_issue": "No", 
            "time_frame": "up to 12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02132169"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Safety measures (adverse events, etc.) of AC 170 0.024% compared to its vehicle will be measured at Visit 1-4 and 5 (for subset of patients).", 
            "measure": "Safety of AC 170 0.024% compared to its vehicle", 
            "safety_issue": "No", 
            "time_frame": "Up to 12 Weeks"
        }, 
        "source": "Aciex Therapeutics, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Aciex Therapeutics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}